Hydrodynamic-based delivery of PTP1B shRNA reduces plasma glucose levels in diabetic mice

Vakili,Sanaz; Ebrahimi,Shadi   Sadat Seyyed; Sadeghi,Asie; Gorgani-Firuzjaee,Sattar; Beigy,Maani; Pasalar,Parvin; Meshkani,Reza

doi:10.3892/mmr.2012.1172

Hydrodynamic-based delivery of PTP1B shRNA reduces plasma glucose levels in diabetic mice

Authors:
- Sanaz Vakili
- Shadi Sadat Seyyed Ebrahimi
- Asie Sadeghi
- Sattar Gorgani-Firuzjaee
- Maani Beigy
- Parvin Pasalar
- Reza Meshkani
View Affiliations

Affiliations: Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Published online on: November 8, 2012 https://doi.org/10.3892/mmr.2012.1172
Pages: 211-216

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of insulin signaling which is overexpressed in the liver of diabetic animals. The aims of this study were to generate liver-specific PTP1B knockout mice using a PTP1B‑short hairpin RNA (shRNA) plasmid and to investigate the effect of PTP1B inhibition on plasma glucose levels in streptozotocin-induced diabetic mice. We first validated the hydrodynamic tail vein injection in mice using a vector carrying the luciferase gene. Expression of the PTP1B gene was quantified by real-time PCR. The level of phosphorylated Akt was examined by western blot analysis. The injection of the plasmid containing firefly luciferase revealed that the highest transfer of the vector into the liver was obtained 24 h after the injection of 20 µg plasmid. The injection of PTP1B-shRNA, but not the scrambled shRNA plasmid, resulted in a reduction in PTP1B expression levels by up to 84% in the liver of the diabetic mice. Plasma glucose levels following the injection of PTP1B-shRNA remained significantly lower in the diabetic mice for 5 days. In addition, mice receiving PTP1B-shRNA in the basal and insulin-stimulated states had higher levels of Akt phosphorylation in the liver cells compared with mice that were injected with the scrambled sequence (35 and 60%, respectively; p<0.01). Furthermore, PTP1B overexpression was observed in the muscle, liver, adipose, heart and kidney tissues of the diabetic mice. The data from this study demonstrate that PTP1B inhibition may be a promising approach for lowering plasma glucose levels in diabetic patients. However, further studies using non-viral carriers are required to deliver the plasmid safely into the liver.

View Figures

View References

1	Goldstein BJ: Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. Receptor. 3:1–15. 1993.PubMed/NCBI
2	Zabolotny JM, Haj FG, Kim YB, Kim HJ, et al: Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem. 279:24844–24851. 2004. View Article : Google Scholar
3	Elchebly M, Payette P, Michaliszyn E, et al: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 283:1544–1548. 1999. View Article : Google Scholar : PubMed/NCBI
4	Klaman LD, Boss O, Peroni OD, et al: Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol. 20:5479–5489. 2000. View Article : Google Scholar : PubMed/NCBI
5	Nieto-Vazquez I, Fernández-Veledo S, de Alvaro C, Rondinone CM, Valverde AM and Lorenzo M: Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance. Diabetes. 56:404–413. 2007. View Article : Google Scholar
6	Dadke SS, Li HC, Kusari AB, Begum N and Kusari J: Elevated expression and activity of protein-tyrosine phosphatase 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats. Biochem Biophys Res Commun. 274:583–589. 2000. View Article : Google Scholar : PubMed/NCBI
7	Ahmad F, Azevedo JL, Cortright R, Dohm GL and Goldstein BJ: Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest. 100:449–458. 1997. View Article : Google Scholar : PubMed/NCBI
8	Wu Y, Ouyang JP, Wu K, Wang SS, Wen CY and Xia ZY: Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats. Br J Pharmacol. 146:234–243. 2005. View Article : Google Scholar : PubMed/NCBI
9	Adeli K, Macri J, Mohammadi A, Kito M, Urade R and Cavallo D: Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells. J Biol Chem. 272:22489–22494. 1997. View Article : Google Scholar : PubMed/NCBI
10	Zabolotny JM, Kim YB, Welsh LA, Kershaw EE, Neel BG and Kahn BB: Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem. 283:14230–14241. 2008. View Article : Google Scholar : PubMed/NCBI
11	Parvaneh L, Meshkani R, Bakhtiyari S, et al: Palmitate and inflammatory state additively induce the expression of PTP1B in muscle cells. Biochem Biophys Res Commun. 396:467–71. 2010. View Article : Google Scholar : PubMed/NCBI
12	MohammadTaghvaei N, Meshkani R, Taghikhani M, Larijani B and Adeli K: Palmitate enhances protein tyrosine phosphatase 1B (PTP1B) gene expression at transcriptional level in C2C12 skeletal muscle cells. Inflammation. 34:43–48. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wu J, Yang LJ and Zou DJ: Rosiglitazone attenuates tumor necrosis factor-α-induced protein-tyrosine phosphatase-1B production in HepG2 cells. J Endocrinol Invest. 35:28–34. 2012.
14	Haj FG, Zabolotny JM, Kim YB, Kahn BB and Neel BG: Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B^−/− mice. J Biol Chem. 280:15038–15046. 2005. View Article : Google Scholar : PubMed/NCBI
15	Delibegovic M, Bence KK, Mody N, et al: Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol. 27:7727–7734. 2007. View Article : Google Scholar : PubMed/NCBI
16	Gu P, Jiang W, Du H, Shao J, Lu B, Wang J and Zou D: Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population. J Endocrinol Invest. 33:483–488. 2010. View Article : Google Scholar : PubMed/NCBI
17	Meshkani R, Taghikhani M, Al-Kateb H, Larijani B, et al: Polymorphisms within the protein tyrosine phosphatase 1B (PTPN1) gene promoter: functional characterization and association with type 2 diabetes and related metabolic traits. Clin Chem. 53:1585–1592. 2007. View Article : Google Scholar
18	Meshkani R, Taghikhani M, Mosapour A, et al: 1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population. Arch Med Res. 38:556–562. 2007. View Article : Google Scholar : PubMed/NCBI
19	Delibegovic M, Zimmer D, Kauffman C, et al: Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes. 58:590–599. 2009. View Article : Google Scholar
20	Swarbrick MM, Havel PJ, Levin AA, et al: Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology. 150:1670–1679. 2009. View Article : Google Scholar
21	Koren S and Fantus IG: Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 21:621–40. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhang S and Zhang ZY: PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today. 12:373–381. 2007. View Article : Google Scholar : PubMed/NCBI
23	Xu J, Li L, Hong J and Huang W: Effects of small interference RNA against PTP1B and TCPTP on insulin signaling pathway in mouse liver: evidence for non-synergetic cooperation. Cell Biol Int. 31:88–91. 2007. View Article : Google Scholar : PubMed/NCBI
24	Bakhtiyari S, Meshkani R, Taghikhani M, Larijani B and Adeli K: Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Lipids. 45:237–244. 2010. View Article : Google Scholar : PubMed/NCBI
25	Maruyama H, Higuchi N, Nishikawa Y, et al: High level expression of naked DNA delivered to rat liver via tail vein injection. J Gene Med. 4:333–341. 2002. View Article : Google Scholar : PubMed/NCBI
26	Meshkani R and Adeli K: Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem. 42:1331–1346. 2009. View Article : Google Scholar : PubMed/NCBI
27	Liu F, Song YK and Liu D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6:1258–1266. 1999. View Article : Google Scholar : PubMed/NCBI
28	McAnuff MA, Rettig GR and Rice KG: Potency of siRNA versus shRNA mediated knockdown in vivo. J Pharm Sci. 96:2922–2930. 2007. View Article : Google Scholar
29	Ventura-Sobrevilla J, Boone-Villa VD, Aguilar CN, et al: Effect of varying dose and administration of streptozotocin on blood sugar in male CD1 mice. Proc West Pharmacol Soc. 54:5–9. 2011.PubMed/NCBI
30	Lewis DL and Wolff JA: Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev. 59:115–123. 2007. View Article : Google Scholar : PubMed/NCBI
31	Galic S, Hauser C, Kahn BB, et al: Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol. 25:819–829. 2005. View Article : Google Scholar : PubMed/NCBI